# US 2011/0212139 A1 · High-density lipoprotein coated medical devices

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2011/0212139 A1
- Document ID: US20110212139A1
- Status: Published application
- Kind: A1
- Application number: 13/102,791
- Filed: 2011-05-06
- Published: 2011-09-01
- Earliest claimed: 2004-01-02
- Assignees: Advanced Cardiovascular Systems, Inc.
- Inventors: Ni Ding
- Web page: https://patentgrep.com/patent/US20110212139A1

## CPC

- A61L 31/16: Biologically active materials, e.g. therapeutic substances {(A61L31/047 takes precedence)}
- A61F 2/82: Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents (stent-grafts for tubular structures of the body other than blood vessels A61F2/04; stent-grafts for blood vessels A61F2/07)
- A61K 38/1709: {from mammals}
- A61L 31/10: Macromolecular materials
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 13/02: of urine or of the urinary tract, e.g. urine acidifiers
- A61L 2300/252: Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
- A61L 2300/416: Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61F: FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS (dental prosthetics A61C)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Method are disclosed for local and systemic administration HDL, recombinant HDL or HDLm for the prevention, treatment, or amelioration of a vascular disorder, disease or occlusion such as restenosis or vulnerable plaque.

## Claims

### Claim 1

A method of treating a medical condition, comprising implanting in a human being an implantable medical device, wherein the implantable medical device comprises
a coating comprising a hydrophobic polymer and a high-density lipoprotein mimic (HDLm) and a biobeneficial material,
wherein the hydrophobic polymer is a polyester selected from the group consisting of poly(D, L-lactic acid) (PDLLA), poly(L-lactic acid) (PLLA), poly(D-lactic acid) (PDLA), poly(D, L-lactic acid-co-glycolic acid) (PDLLGA), poly(glycolic acid) (PGA), polyhydroxyalkanoates (PHA), poly(3-hydroxybutyrate) (PHB), poly(3-hydroxybutyrate-co-3-hydroxyvalerate), poly(3-hydroxyvalerate), poly(3-hydroxyhexanoate), poly(4-hydroxybutyrate), poly(4-hydroxyvalerate), poly(4-hydroxyhexanoate), polycaprolactone (PCL), and a combination thereof,
wherein the implantable medical device comprises a stent suitable for use in a blood vessel, and
wherein HDLm comprises a polypeptide moiety that mimics the structure or function of a domain of apoA-I, apoA-II, or AI/AII-HDL.

### Claim 2 (depends on 1)

The method of claim 1 wherein the medical condition is selected from the group consisting of vulnerable plaque, restenosis, stenosis, atherosclerosis, thrombosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, chronic total occlusion, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, and a combination thereof.

### Claim 3

A method of treating a vascular disorder of a patient, comprising implanting in the patient an implantable medical device, wherein the implantable medical device comprises
a coating comprising a hydrophobic polymer and a high-density lipoprotein mimic (HDLm) and a biobeneficial material,
wherein the hydrophobic polymer is a polyester selected from the group consisting of poly(D, L-lactic acid) (PDLLA), poly(L-lactic acid) (PLLA), poly(D-lactic acid) (PDLA), poly(D, L-lactic acid-co-glycolic acid) (PDLLGA), poly(glycolic acid) (PGA), polyhydroxyalkanoates (PHA), poly(3-hydroxybutyrate) (PHB), poly(3-hydroxybutyrate-co-3-hydroxyvalerate), poly(3-hydroxyvalerate), poly(3-hydroxyhexanoate), poly(4-hydroxybutyrate), poly(4-hydroxyvalerate), poly(4-hydroxyhexanoate), polycaprolactone (PCL), and a combination thereof,
wherein the implantable medical device comprises a stent suitable for use in a blood vessel, and
wherein HDLm comprises a polypeptide moiety that mimics the structure or function of a domain of apoA-I, apoA-II, or AI/AII-HDL.

### Claim 4 (depends on 3)

The method of claim 3, wherein the disorder is vulnerable plaque, restenosis, stenosis, atherosclerosis, or thrombosis.

### Claim 5 (depends on 3)

The method of claim 3, wherein local administration is via a stent.

### Claim 6 (depends on 3)

The method of claim 3, additionally comprising implanting a stent in the patient.

### Claim 7 (depends on 6)

The method of claim 6, wherein the stent includes a drug in a body of the stent or in a coating on the stent.

### Claim 8 (depends on 3)

The method of claim 3, wherein the patient is a type I or type II diabetic.

### Claim 9 (depends on 3)

The method of claim 3, wherein the patient is a diabetic.

### Claim 10 (depends on 1)

The method of claim 1, wherein the implantable medical device is a stent.

### Claim 11 (depends on 3)

The method of claim 3, wherein the implantable medical device is a stent.
